Intervacc’s developmental program for new vaccines against animal infectious diseases is summarised in the following table. Please, click on respective project name or indication to read more.

ProjectDisease areaSpeciesPreclinicalClinical RegulatoryMarket
INV-274S.suis infectionPiglets
S. aureus antigenS.aureus mastitisCow

The successful  clinical trials with vaccination against strangles using Strangvac®, based on recombinant proteins, demonstrate a proof of concept for our technology. In contrast to conventional vaccines, using attenuated live strains, our technology using recombinant proteins as antigens results in a safe and efficacious vaccine with very low incidence of unwanted side effects.